FDA of­fers quick re­view for Shire's prospec­tive block­buster lanadelum­ab; Big Phar­ma loves big buy­backs

→  The FDA is help­ing Shire $SH­PG hus­tle along its ap­pli­ca­tion for lanadelum­ab, which the big biotech be­lieves can peak out at $2 bil­lion in rev­enue if it can get ap­proved for hered­i­tary an­gioede­ma. The agency ac­cept­ed their ap­pli­ca­tion and pro­vid­ed a pri­or­i­ty re­view with a PDU­FA date of Au­gust 26.

→ What’s bio­phar­ma do­ing with its big tax re­form wind­fall? Well, stock buy­backs is grab­bing the li­on’s share of it so far. Ax­ios tal­lied up $50 bil­lion in buy­backs an­nounced to date, which isn’t sit­ting well with every­one in the in­dus­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER